Immuneering Q2 2026: $182.7M Cash, Phase 3 Pancreatic Cancer Trial Underway, 17.3-Month Survival Data
IMRX sits 46% above its 52-week low of $2.9.
Summary
Immuneering's Q2 2026 update highlights a strong cash position of $182.7 million, the launch of its Phase 3 pancreatic cancer trial, and positive survival data from its lead drug candidate.
Key Events · Earnings and Guidance · IMRX
-
Q2 2026 Financial Results
Net loss of $17.3 million ($0.27/share) vs. $14.4 million ($0.40/share) in Q2 2025. Cash, cash equivalents and marketable securities totaled $182.7 million as of June 30, 2026, with runway expected into 2029.
-
Phase 3 Trial Underway
The pivotal MAPKeeper 301 trial evaluating atebimetinib + chemotherapy in first-line pancreatic cancer is dosing patients, with over 30 study locations posted on clinicaltrials.gov.
-
Compelling Phase 2a Survival Data
17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP, presented at ASCO 2026. 84% of evaluable patients were weight stable or gained weight at 3 months.
-
Upcoming Milestones
Phase 2 trial in non-small cell lung cancer to dose first patient in 2H 2026, with preliminary data expected late 2027. Phase 3 topline data readout anticipated mid-2028.
Analysis · IMRX · Life Sciences
Immuneering's Q2 2026 update underscores its late-stage momentum and financial footing. A net loss of $17.3 million was reported, while $182.7 million in cash extends the runway into 2029. The pivotal Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer is now dosing patients, supported by compelling Phase 2a data that showed a 17.3-month median overall survival and a favorable tolerability profile. Although the net loss widened year-over-year as R&D spending increased, the company's clinical progress and strong balance sheet stand out.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMRX was trading at $4.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $284.7M. The 52-week trading range was $2.90 to $10.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.